Condition: Relapsed Refractory Multiple Myeloma (RRMM) · Sponsor: Seoul National University Hospital
This is an open-label, single arm, multicenter study to evaluate the efficacy of letermovir in the prevention of clinically significant CMV infection in adult, CMV-seropositive relapsed/refractory MM patients undergoing BsAbs therapy.
This description comes directly from the study's public registry record.
Ja Min Byun, MD, PhD · 82-2-2072-7215 · jaminbyun@snu.ac.kr
Always discuss trial participation with your own doctor first.
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06920251